-
1
-
-
39149113165
-
Development of the 21-gene assay and its application in clinical practice and clinical trials
-
Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26:721-8
-
(2008)
J Clin Oncol
, vol.26
, pp. 721-728
-
-
Sparano, J.A.1
Paik, S.2
-
2
-
-
34247516968
-
-
National Comprehensive Cancer Network (nccn), Ver. 1.2010. Fort Washington, PA: nccn
-
National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Ver. 1.2010. Fort Washington, PA: nccn; 2010
-
(2010)
NCCN Clinical Practice Guidelines In Oncology: Breast Cancer
-
-
-
4
-
-
70450190156
-
-
Canadian Cancer Society and the National Cancer Institute of Canada, Toronto, ON: Canadian Cancer Society
-
Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2008. Toronto, ON: Canadian Cancer Society; 2008
-
(2008)
Canadian Cancer Statistics 2008
-
-
-
5
-
-
34347356514
-
Current St Gallen recommendations on primary therapy of early breast cancer
-
Persing M, Grosse R. Current St Gallen recommendations on primary therapy of early breast cancer. Breast Care (Basel) 2007;2:137-40
-
(2007)
Breast Care (Basel)
, vol.2
, pp. 137-140
-
-
Persing, M.1
Grosse, R.2
-
6
-
-
19944422061
-
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
-
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26
-
(2004)
N Engl J Med
, vol.351
, pp. 2817-2826
-
-
Paik, S.1
Shak, S.2
Tang, G.3
-
7
-
-
33748693297
-
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
-
Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 1183-1192
-
-
Buyse, M.1
Loi, S.2
Van't veer, L.3
-
8
-
-
0037137519
-
A gene-expression signature as a predictor of survival in breast cancer
-
van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009
-
(2002)
N Engl J Med
, vol.347
, pp. 1999-2009
-
-
van de Vijver, M.J.1
He, Y.D.2
Van't veer, L.J.3
-
9
-
-
34249052585
-
Predicting response to primary chemotherapy: Gene expression profiling of paraffin-embedded core biopsy tissue
-
Mina L, Soule SE, Badve S, et al. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat 2007;103:197-208
-
(2007)
Breast Cancer Res Treat
, vol.103
, pp. 197-208
-
-
Mina, L.1
Soule, S.E.2
Badve, S.3
-
10
-
-
33750598939
-
The hoxb13:Il17br expression index is a prognostic factor in early-stage breast cancer
-
Ma XJ, Hilsenbeck SG, Wang W, et al. The hoxb13:il17br expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 2006;24:4611-19
-
(2006)
J Clin Oncol
, vol.24
, pp. 4611-4619
-
-
Ma, X.J.1
Hilsenbeck, S.G.2
Wang, W.3
-
11
-
-
33750895236
-
Tailorx: Trial assigning individualized options for treatment (Rx)
-
Sparano JA. tailorx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006;7: 347-50
-
(2006)
Clin Breast Cancer
, vol.7
, pp. 347-350
-
-
Sparano, J.A.1
-
12
-
-
33947196825
-
Impact of a 21-gene rt-pcr assay on t reatment decisions i n early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies
-
Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene rt-pcr assay on t reatment decisions i n early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 2007;109:1011-18
-
(2007)
Cancer
, vol.109
, pp. 1011-1018
-
-
Lyman, G.H.1
Cosler, L.E.2
Kuderer, N.M.3
Hornberger, J.4
-
13
-
-
59849127767
-
Recommendations from the egapp Working Group: Can tumor gene expression profiling improve outcomes in patients with breast cancer?
-
Evaluation of Genomic Applications in Practice and Prevention (egapp) Working Group
-
Evaluation of Genomic Applications in Practice and Prevention (egapp) Working Group. Recommendations from the egapp Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 2009;11:66-73
-
(2009)
Genet Med
, vol.11
, pp. 66-73
-
-
-
14
-
-
85168679425
-
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: An evidence-based and economic analysis
-
Health Quality Ontario
-
Health Quality Ontario. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Ont Health Technol Assess Ser 2010;10:1-57
-
(2010)
Ont Health Technol Assess Ser
, vol.10
, pp. 1-57
-
-
-
15
-
-
84898780568
-
-
United Kingdom, National Institute for Health and Clinical Excellence (nice)., London, UK: nice
-
United Kingdom, National Institute for Health and Clinical Excellence (nice). Gene Expression Profiling and Expanded Immunohistochemistry Tests to Guide the Use of Adjuvant Chemotherapy in Breast Cancer Management: MammaPrint, Oncotype dx, IHC4, and Mammostrat. London, UK: nice; 2012
-
(2012)
Gene Expression Profiling and Expanded Immunohistochemistry Tests to Guide the Use of Adjuvant Chemotherapy In Breast Cancer Management: MammaPrint, Oncotype Dx, IHC4, and Mammostrat
-
-
-
17
-
-
36849069347
-
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
-
Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312
-
(2007)
J Clin Oncol
, vol.25
, pp. 5287-5312
-
-
Harris, L.1
Fritsche, H.2
Mennel, R.3
-
18
-
-
52049089470
-
Does Oncotype dx recurrence score affect the management of patients with earlystage breast cancer?
-
Asad J, Jacobson AF, Estabrook A, et al. Does Oncotype dx recurrence score affect the management of patients with earlystage breast cancer? Am J Surg 2008;196:527-9
-
(2008)
Am J Surg
, vol.196
, pp. 527-529
-
-
Asad, J.1
Jacobson, A.F.2
Estabrook, A.3
-
19
-
-
42649098952
-
Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer
-
Oratz R, Paul D, Cohn AL, Sedlacek SM. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 2007;3:182-6
-
(2007)
J Oncol Pract
, vol.3
, pp. 182-186
-
-
Oratz, R.1
Paul, D.2
Cohn, A.L.3
Sedlacek, S.M.4
-
20
-
-
77950494285
-
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection
-
Lo SS, Mumby PB, Norton J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010;28:1671-6
-
(2010)
J Clin Oncol
, vol.28
, pp. 1671-1676
-
-
Lo, S.S.1
Mumby, P.B.2
Norton, J.3
-
21
-
-
65449138790
-
The influence of a gene expression profile on breast cancer decisions
-
Henry LR, Stojadinovic A, Swain SM, et al. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 2009;99:319-23
-
(2009)
J Surg Oncol
, vol.99
, pp. 319-323
-
-
Henry, L.R.1
Stojadinovic, A.2
Swain, S.M.3
-
22
-
-
35648995985
-
Women's interest in gene expression analysis for breast cancer recurrence risk
-
O'Neill SC, Brewer NT, Lillie SE, et al. Women's interest in gene expression analysis for breast cancer recurrence risk. J Clin Oncol 2007;25:4628-34
-
(2007)
J Clin Oncol
, vol.25
, pp. 4628-4634
-
-
O'Neill, S.C.1
Brewer, N.T.2
Lillie, S.E.3
-
24
-
-
77951019146
-
Women's experiences with genomic testing for breast cancer recurrence risk
-
Tzeng JP, Mayer D, Richman AR, et al. Women's experiences with genomic testing for breast cancer recurrence risk. Cancer 2010;116:1992-2000
-
(2010)
Cancer
, vol.116
, pp. 1992-2000
-
-
Tzeng, J.P.1
Mayer, D.2
Richman, A.R.3
-
25
-
-
78650674744
-
Knowledge of genomic testing among early-stage breast cancer patients
-
Richman AR, Tzeng JP, Carey LA, Retèl VP, Brewer NT. Knowledge of genomic testing among early-stage breast cancer patients. Psychooncology 2011;20:28-35
-
(2011)
Psychooncology
, vol.20
, pp. 28-35
-
-
Richman, A.R.1
Tzeng, J.P.2
Carey, L.A.3
Retèl, V.P.4
Brewer, N.T.5
-
26
-
-
33847752170
-
Retention and use of breast cancer recurrence risk information from genomic tests: The role of health literacy
-
Lillie SE, Brewer NT, O'Neill SC, et al. Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacy. Cancer Epidemiol Biomarkers Prev 2007;16:249-55
-
(2007)
Cancer Epidemiol Biomarkers Prev
, vol.16
, pp. 249-255
-
-
Lillie, S.E.1
Brewer, N.T.2
O'Neill, S.C.3
-
27
-
-
69049109085
-
When genomic and standard test results diverge: Implications for breast cancer patients' preference for chemotherapy
-
Brewer NT, Edwards AS, O'Neill SC, Tzeng JP, Carey LA, Rimer BK. When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy. Breast Cancer Res Treat 2009;117:25-9
-
(2009)
Breast Cancer Res Treat
, vol.117
, pp. 25-29
-
-
Brewer, N.T.1
Edwards, A.S.2
O'Neill, S.C.3
Tzeng, J.P.4
Carey, L.A.5
Rimer, B.K.6
-
28
-
-
84857038599
-
Tailored chemotherapy based on tumour gene expression analysis: Breast cancer patients' misinterpretations and positive attitudes
-
Pellegrini I, Rapti M, Extra JM, et al. Tailored chemotherapy based on tumour gene expression analysis: breast cancer patients' misinterpretations and positive attitudes. Eur J Cancer Care (Engl) 2012;21:242-50
-
(2012)
Eur J Cancer Care (Engl)
, vol.21
, pp. 242-250
-
-
Pellegrini, I.1
Rapti, M.2
Extra, J.M.3
|